Physician in the Loop
For youSign inAsk
Pathology ·

Score from routine H&E slides stratifies pancreatic cancer survival; Aignostics launches AI suite for H&E slides; Evident unveils benchtop scanner

A laboratory microscope with binocular eyepieces, objectives and focus knobs, and a glass slide on its stage holding a soft amber stained section.
THE SHORT READ

A Modern Pathology study published Oct. 14 found that TIGERS, a risk score from routine hematoxylin and eosin (H&E) histology, separated survival after pancreatic cancer resection in a prospectively accrued cohort.

Aignostics launched four research-use AI products for whole-slide H&E images, and Evident announced a benchtop whole slide imaging scanner for small and medium-sized labs.

THE DETAILS
  • Research Oct 14, 2026
    TIGERS score from routine H&E histology stratifies survival after pancreatic cancer resection, Modern Pathology study finds
    In a multicohort study published Oct. 14 in Modern Pathology, TIGERS, a nine-feature score from routine hematoxylin and eosin (H&E) whole-slide images, was tested in resected pancreatic ductal adenocarcinoma. In a prospectively accrued cohort, mortality was 47.5% in the high-risk group and 22.7% in the low-risk group, and high risk remained associated with worse survival after adjustment (hazard ratio, 4.45; 95% CI 2.28 to 8.70; P < .001). Adding TIGERS increased Harrell's C-index in all six retrospective cohorts, but in one external cohort the fixed cutoff classified 226 of 235 patients (96.2%) as high risk.
    Sources: Modern Pathology, PubMed
  • AI Oct 16, 2026
    Aignostics launches HETA Clinical, four research-use AI tools for slide quality, tumor detection, mitoses and cellularity
    Aignostics said Oct. 16 that HETA Clinical, a family of pan-cancer AI products, measure slide quality, tumor presence, mitotic counts and tumor cellularity across whole slide H&E images. HETA Tumor Detect flags cases likely to contain tumor at scanning, and HETA Tumor Cellularity proposes a region with sufficient tumor content. Pathologists the company spoke with estimate that 10% to 20% of molecular tests fail because tissue lacks enough tumor, the company said. The products are for research use only and not for diagnostic procedures.
    Source: Aignostics
  • Technology Oct 16, 2026
    Evident unveils Pramana POD whole slide scanner for small and medium-sized labs, rated at 25 slides an hour
    Evident announced Oct. 16 the Pramana POD benchtop whole slide imaging scanner, built for small and medium-sized laboratories, with true 40X imaging at 25 slides per hour under defined conditions, the company said. Its volumetric imaging captures multiple focal planes, and built-in image-quality assessment helps deliver pathologist-ready whole slide images, according to the company. The scanner is for research use only, and future clinical availability is subject to regulatory authorization.
    Source: Evident

The weekly innovation roundup for pathology, published every Sunday for the week before; every item links to its sources. Latest pathology news · All specialties